| Literature DB >> 30358165 |
Adetomiwa Ayodele Adeniji1,2, Oluwole Samuel Aremu3, Olubukola Oluranti Babalola1,2.
Abstract
The results of this study indicate that the maize rhizosphere remains a reservoir for microbial strains with unique beneficial properties. The study sought to provide an indigenous Bacillus strain with a bioprotective potential to alleviate maize fusariosis in South Africa. We selected seven Bacillus isolates (MORWBS1.1, MARBS2.7, VERBS5.5, MOREBS6.3, MOLBS8.5, MOLBS8.6, and NWUMFkBS10.5) with biosuppressive effects against two maize fungal pathogens (Fusarium graminearum and Fusarium culmorum) based on 16S rDNA gene characterization and lipopeptide gene analysis. The PCR analysis revealed that lipopeptide genes encoding the synthesis of iturin, surfactin, and fengycin might be responsible for their antifungal activities. Few of the isolates also showed possible biosurfactant capability, and their susceptibility to known antibiotics is indicative of their eco-friendly attributes. In addition, in silico genomic analysis of our best isolate (Bacillus velezensis NWUMFkBS10.5) and characterization of its active metabolite with FTIR, NMR, and ESI-Micro-Tof MS confirmed the presence of valuable genes clusters and metabolic pathways. The versatile genomic potential of our Bacillus isolate emphasizes the continued relevance of Bacillus spp. in biological management of plant diseases.Entities:
Keywords: zzm321990Bacillus velezensiszzm321990; ESI-Micro-Tof MS; genome; in silico; lipopeptides; plant disease
Mesh:
Substances:
Year: 2018 PMID: 30358165 PMCID: PMC6562122 DOI: 10.1002/mbo3.742
Source DB: PubMed Journal: Microbiologyopen ISSN: 2045-8827 Impact factor: 3.139
Figure 1Colonial characteristics and presumptive identification of the isolated Bacillus strains on HiChrome Bacillus agar
Percentage inhibition of Fusarium graminearum mycelia by Bacillus isolates
| Treatment | Condition (% inhibition zone) | Mean | ||
|---|---|---|---|---|
| 1 | 2 | 3 | ||
| BS1.1 | 42.67 | 46.67 | 66.67 | 52.00b |
| BS2.7 | 42.67 | 41.33 | 56.00 | 46.67cd |
| BS3.5 | 45.33 | 41.33 | 68.00 | 51.56b |
| BS4.3 | 40.00 | 38.67 | 44.00 | 40.89f |
| BS4.6 | 42.67 | 38.67 | 44.00 | 41.78ef |
| BS5.5 | 36.00 | 30.67 | 58.67 | 41.78ef |
| BS6.2 | 32.00 | 26.67 | 69.33 | 42.67ef |
| BS6.3 | 36.00 | 33.33 | 65.33 | 44.89de |
| BS8.5 | 45.33 | 46.67 | 54.67 | 48.89bc |
| BS8.6 | 40.00 | 37.33 | 70.67 | 49.33bc |
| BS10.5 | 54.67 | 42.67 | 77.33 | 58.22a |
| Mean | 41.58b | 38.55c | 61.33a | |
| ANOVA | ||||
| Treatment (T) | *** | |||
| Condition (C) | *** | |||
| T × C | *** | |||
Values are means and standard error of four replicates of in vitro antagonistic activity of selected Bacillus isolates against F. graminearum; values having the same letters are not significantly different according to Duncan's least significant difference test at p ≤ 0.05. 1, 2, and 3 represent conditions of inoculation. *** = treatment, conditions and treatment and conditions are significantly different.
Percentage inhibition of Fusarium culmorum mycelia by Bacillus isolates
| Treatment | Condition (% inhibition zone) | Mean | ||
|---|---|---|---|---|
| 1 | 2 | 3 | ||
| BS1.1 | 37.33 | 34.67 | 60.00 | 44.00e |
| BS2.7 | 44.00 | 41.33 | 62.67 | 49.33d |
| BS3.5 | 45.33 | 46.67 | 57.33 | 49.78cd |
| BS4.3 | 45.33 | 50.67 | 70.67 | 55.56ab |
| BS4.6 | 53.33 | 45.33 | 53.33 | 50.67cd |
| BS5.5 | 45.33 | 44.00 | 65.33 | 51.56cd |
| BS6.2 | 37.33 | 36.00 | 46.67 | 40.00f |
| BS6.3 | 56.00 | 50.67 | 69.33 | 58.67a |
| BS8.5 | 52.00 | 54.67 | 62.67 | 56.44a |
| BS8.6 | 50.67 | 57.33 | 50.67 | 52.89bc |
| BS10.5 | 45.33 | 38.67 | 70.67 | 51.56c |
| Mean | 46.55b | 45.45b | 60.85a | |
| ANOVA | ||||
| Treatment (T) | *** | |||
| Condition (C) | *** | |||
| T × C | *** | |||
Values are means and standard error of four replicates of in vitro antagonistic activity of selected Bacillus isolates against F. culmorum; values same having the same letters are not significantly different according to Duncan's least significant difference test at p ≤ 0.05. 1, 2, and 3 represent conditions of inoculation. *** = treatment, conditions and treatment and conditions are significant different.
Test for biosurfactant properties of potential isolates
| Isolates | Test substance | ||||||
|---|---|---|---|---|---|---|---|
| Drop collapse | |||||||
| Blood agara | Microplate assay | Vegetable oilb | Motor engine oilb | Keroseneb | Hexadecaneb | Parafilmb | |
| BS1.1 | ● | ●● | ● | ● | ● | ● | ● |
| BS3.5 | ● | ○ | ● | ● | ● | ○ | ● |
| BS5.5 | ● | ○ | ○ | ○ | ● | ○ | ○ |
| BS6.3 | ● | ○ | ○ | ○ | ○ | ○ | ○ |
| BS8.5 | ● | ○ | ○ | ○ | ○ | ○ | ○ |
| BS8.6 | ● | ●● | ○ | ● | ● | ● | ● |
| BS10.5 | ● | ●● | ● | ● | ● | ● | ● |
| Water | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| SDS | ● | ●● | ● | ● | ● | ● | ● |
a = hemolysis test: b‐hemolysis (●), no hemolysis (○); b = Drop collapse assay ●: collapse; ○: no collapse; hemolysis test ●: positive; ○: negative; drop collapse test: negative (○), spreading (●), comparable with sds (●); microplate assay: optical distortion comparable with water (○), optical distortion comparable with sds (●●).
Genes detected in the antagonistic Bacillus isolates using specific primers sets
| Primer set | Isolates | ||||||
|---|---|---|---|---|---|---|---|
| BS10.5 | BS8.6 | BS8.5 | BS6.3 | BS5.5 | BS4.6 | BS1.1 | |
| Iturin A ( | ● | ○ | ○ | ● | ○ | ● | ○ |
| 16S ( | ● | ● | ● | ● | ● | ● | ● |
| Surfactins (As1‐F) | ● | ● | ● | ○ | ● | ○ | ● |
| Fengycins (Af2‐F) | ● | ● | ● | ● | ● | ● | ● |
| Surfactin ( | ● | ● | ● | ● | ● | ● | ● |
| Surfactin ( | ● | ○ | ○ | ○ | ○ | ○ | ○ |
| Fengycin ( | ○ | ○ | ○ | ○ | ○ | ○ | ○ |
| Bacillomycin D ( | ● | ○ | ○ | ○ | ○ | ○ | ○ |
|
| ○ | ○ | ○ | ○ | ○ | ○ | ○ |
|
| ○ | ○ | ○ | ○ | ○ | ○ | ○ |
●: (Positive) a PCR amplicon of expected size was seen; ○: negative.
Figure 2Means of three replicates showing activity of BS10.5 extracts on the microbial pathogens at different concentrations. Values are significantly different according to Duncan's least significant difference test at p ≤ 0.05, and means are significantly different from the control
Figure 3Upper plate: inhibitory effect of the BS10.5 extract (20 mg/ml) and fungicide controls (triazole, amphotericin B, and nystatin) (at concentrations 10 µg/ml, respectively), on the Fusarium graminearum and Fusarium culmorum growth in vitro; Lower plate: inhibitory effect of the BS10.5 extract (20 mg/ml) and nystatin (10 µg/ml), on the F. graminearum. For the experiment, n = 4. Activity of the lyophilized extract and commercial fungicide on fungal growth were significantly different at p ≤ 0.05
Figure 4NMR spectrum of BS10.5
Figure 5Positive ESI‐Q‐TOF MS spectrum of lipopeptides extract of BS10.5 strain. Clusters of iturin, surfactin, and bacillomycin (m/z 1,058.6738/1,058.6723, 1,058.6740), fengycin (m/z 1,477.8184), and an unidentified (m/z 2,095.3363) molecular ion species are labeled
Comparison of the Bacillus velezensis NWUMFkBS10.5 genome with other B. velezensis strains
| Attributes |
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|
| Size of genome (bp) | 3,964,473 | 3,989,393 | 4,013,317 | 3,972,310 | 3,918,589 | 3,961,291 | 3,889,532 | 4,009,746 | 3,917,761 | 4,206,167 |
| G+C numbers (%) | 46.39 | 46.68 | 40.32 | 46.5% | 46.49 | 46.60 | 46.71 | 46.49 | 46.40 | 46.03 |
| Number of coding sequences | 3,875 | 3,531 | 3,369 | 3,777 | 3,693 | 3,861 | 3,656 | 3,953 | 3,643 | 4,436 |
| Total genes | 3,916 | 3,866 | 3,789 | n.d | 3,421 | 4,037 | n.d | 4,114 | n.d | n.d |
| tRNA | 89 | 86 | 87 | 75 | 89 | 89 | 89 | 95 | 72 | 86 |
| rRNA | 13 | 27 | 27 | 7 | 9 | 29 | 10 | 30 | 7 | 27 |
| Number of RNAs | 93 | n.d | n.d | n.d | 117 | 118 | 182 | 161 | n.d | n.d |
n.d: not documented
Figure 6Subsystem summary of the genome Bacillus velezensis NWUMFkBS10.5 predicted by SEED Viewer v2.0. Genomic features are colored according to their functional classification types (Overbeek et al., 2014)
Description and location of BGC in NWUMFkBS10.5 identified in silico
| Cluster Identity (ID) | Type | Position/Region | Numbers of BGC | Most Similar BGC predicted | Percentage similarity |
|---|---|---|---|---|---|
| Cluster 1 (218.374_ID_10360) | Terpene | 42,380–64,263 | 1 | Undefined | — |
| Cluster 2 (237.089_ID_10346) | Otherks | 65,373–106,617 | 1 | Butirosin | 7% of genes similar |
| Cluster 3 (237.089_ID_10346) | Terpene | 189,395–210,135 | 1 | Undefined | — |
| Cluster 4 (237.089_ID_10346) | Transatpks | 493,558–579,439 | 5 | Macrolactin | 100% of genes similar |
| Cluster 5 (237.089_ID_10346) | Transatpks—Nrps | 808,101–910,775 | 10 | Bacillaene | 100% of genes similar |
| Cluster 6 (237.089_ID_10346) | Transatpks—Nrps | 973,335 –1,061,819 | 10 | Fengycin | 86% of genes similar |
| Cluster 7 (228.907_ID_10356) | Transatpks | 1–45,825 | 10 | Difficidin | 53% of genes similar |
| Cluster 8 (228.907_ID_10356) | T3pks | 161,376–202,527 | 1 | Undefined | — |
| Cluster 9 (242.696_ID_1037) | Nrps | 1–10,331 | 1 | Undefined | — |
| Cluster 10 (242.696_ID_1037) | Nrps | 1–14,180 | 2 | Fengycin | 13% of genes similar |
| Cluster 11 (232.565_ID_10370) | Transatpks | 1–23,720 | 7 | Difficidin | 26% of genes similar |
| Cluster 12 (246.163_ID_10350) | Nrps | 516,770–569,433 | 1 | undefined | — |
| Cluster13 (263.57_ID_10354) | Nrps | 1–25,748 | 3 | Surfactin | 47% of genes similar |
| Cluster 14 (265.136_ID_10348) | Bacteriocin—Nrps | 1,981–68,772 | 10 | Bacillibactin | 100% of genes similar |
| Cluster 15 (265.136_ID_10348) | Other | 574,581–615,999 | 6 | Bacilysin | 100% of genes similar |
| Cluster 16 (265.136_ID_10348) | Lantipeptide | 766,502–789,690 | 1 | Mersacidin | 90% of genes similar |
Overview of the biosynthetic compounds predicted in the NWUMFkBS10.5 genome
| Biosynthetic compound | Cluster located | Biomedical/Biocontrol function | Reference |
|---|---|---|---|
| Mycosubtilin | 6 | Antifungal, hemolytic, and limited antibacterial activity | Duitman et al. ( |
| Fengycin and Plipastatin | 6 | Broad‐spectrum antifungal and antitumoral agent | Cochrane and Vederas ( |
| Surfactin | 13 | Antibacterial, antifungal, antiviral, antimycoplasma, antitumoral, insecticidal, anticoagulant activities, and enzyme inhibitors | Mnif and Ghribi ( |
| Iturin | 6 | Antibacterial and antifungal activity | Dunlap et al. ( |
| Polymyxin | 6 | Antibacterial, antifungal, and Immuno‐modulating activity | Cochrane et al. ( |
| Sessilin | 10 | Antifungal activity | D’Aes et al. ( |
| Bananamides | 10 | Unspecified | Nguyen et al. ( |
| Cichopeptin | 10 | Limited information | Huang et al. ( |
| Viscosin | 10 | Biosurfactant | Alsohim et al. ( |
| Taiwachelin, tolaasinand, orfamide | 10 | Iron chelation, therapeutic peptide, insecticidal biosurfactant, and elicitor of induced systemic resistance | Andolfi, Cimmino, Cantore, Iacobellis, and Evidente ( |
| Mersacidin | 16 | Antibacterial | Abriouel, Franz, Ben Omar, and Gálvez ( |
| Bacitracin and bacilysin | 15 | Limited use as animal growth promoter, topical antibiotic, antibacterial, and antifungal | Mousa and Raizada ( |
| Bacillibactin, paenibactin, griseobactin, heterobactin, mirubactin, myxochelin, vanchrobactin | 14 | Iron chelation and anticancer agent | Balado, Osorio, and Lemos ( |
| Amylocyclicin | 1 | Antibacterial and plant growth promoter | Scholz et al. ( |
| Lichenysin | 13 | Biosurfactant | Grangemard, Bonmatin, Bernillon, Das, and Peypoux ( |
| Basiliskamides | 13 | Antifungal | Theodore et al. ( |
| Difficidin | 11, 7, 4 | Broad‐spectrum antibacterial compound | Chen et al. ( |
| Kalimantacin/batumin and oocydin A | 11, 7, 5 | Antibacterial and antifungal haterumalide | Matilla, Leeper, and Salmond ( |
| Sorangicin | 11, 7 | Antibacterial macrolide antibiotic | Campbell et al. ( |
| Elansolid | 7 | Antibiotic (Bactericidal) | Steinmetz et al. ( |
| Myxovirescin | 7, 5 | Antibiotic (Bactericidal) | Xiao, Gerth, Müller, and Wall ( |
| Phormidolide, thiomarinol, and mupirocin | 5 | Antitumor agent and antibacterial metabolite/clinical antibiotic | Mousa and Raizada ( |
| Paenilarvins, tridecaptin, and paenibacterin | 6 | Antifungal, antitumor agent, and antibiotic (Bactericidal) | Cochrane et al. ( |
Figure 7Neighbor‐joining phylogenetic tree from pangenomic sequence of closely related Bacillus velezensis strains. Bar, 0.01 substitutions per nucleotide position. Reference strains highlighted green. Strain B. velezensis NWUMFkBS10.5 is highlighted yellow
Figure 8Pangenomic atlas of Bacillus velezensis NWUMFkBS10.5, other closely related B. veleznesis strains, and an out group B. cellulosilyticus DSM 2522 (genome 4). The similarities and dissimilarities in their core and non‐core genome are indicated as predicted in the left key of the figure. Peculiar genes in strain B. velezensis NWUMFkBS10.5 are indicated in its ring as light blue arcs